ARTICLE | Company News
FDA to review Galenica's PA21 for CKD
April 16, 2013 12:41 AM UTC
Galenica Ltd. (SIX:GALN) and its specialty pharma business Vifor Pharma Ltd. said FDA accepted for review an NDA for PA21 to treat hyperphosphatemia in patients with chronic kidney disease (CKD). The ...